Medical products company UFP Technologies (NASDAQ: UFPT) beat Wall Street’s revenue expectations in Q3 2026, with sales up 11.6% year on year to $172.4 million. Its non-GAAP profit of $2.88 per share was 7.3% above analysts’ consensus estimates.
Is now the time to buy UFPT? Find out in our full research report (it’s free for active Edge members).
UFP Technologies (UFPT) Q3 2026 highlights:
- Revenue $172.4 million vs S&P analysts’ estimates of $167 million (11.6% year-on-year growth, 3.2% beat)
- Adjusted EPS $2.88 vs S&P analysts’ estimates of $2.69 (7.3% beat)
- Adjusted EBITDA $35.43 million vs analyst estimates of $33.95 million (20.5% margin, 4.4% beat)
- Operating margin 16%, in line with the same quarter last year
- Market capitalization $2.17 billion
StockStory’s take
UFP Technologies delivered a positive third quarter, with revenue and adjusted earnings per share both surpassing Wall Street expectations. The market responded strongly, reflecting management’s ability to drive organic growth across its MedTech portfolio. CEO Mitch Rock highlighted demand strength in segments like patient beds, cardiovascular, infection control, and orthopedics. Rock noted, “What stands out to me is how broad the growth is. MedTech sales were up 12.5% in the quarter, with demand across the portfolio.” The quarter benefited from operational improvements and continued scaling of new programs, especially in the Dominican Republic and within legacy operations.
Looking ahead, management is focused on expanding production capacity, especially within DAS Medical, to support anticipated double-digit growth in high-mix, low-volume medical components. Investments in both organic and inorganic growth are expected to continue, with the recent CI Medical acquisition broadening UFP Technologies’ plastics capabilities. CEO Mitch Rock stated, “We are making progress on several opportunities, and as UFP has grown, so has the size and range of the businesses we can take on.” While ongoing transitions like the AJR offshore move remain a priority, management believes the company is well positioned for further expansion and operational efficiency gains in 2027.
Key insights from management’s remarks
Management attributed the quarter’s outperformance to strong organic sales, operational improvements, and broad-based MedTech demand, while making strategic investments and acquisitions to strengthen future capabilities.
- Diverse MedTech segment growth: The company achieved double-digit organic growth in MedTech, with robust demand in patient beds, cardiovascular, infection control, and orthopedic sub-markets. Management emphasized that its growth is not reliant on any single customer or product, reducing concentration risk.
- Operational efficiency gains: Gross margin improved due to better efficiencies in legacy UFP operations and progress in scaling new programs in the Dominican Republic. However, management acknowledged delays in moving AJR production offshore, which they expect to complete by 2027 for further cost savings.
- Targeted capacity investments: UFP Technologies invested in expanding DAS Medical’s manufacturing capacity, aiming to support anticipated double-digit growth in specialized medical components. Management cited new program launches and long-term agreements as foundational to this expansion.
- Acquisition of CI Medical: The August acquisition of CI Medical, a niche medical device printing business, enhances UFP Technologies’ plastics and printing capabilities. Management believes this complements its existing injection molding operations and supports the company’s broader strategy to offer more integrated solutions.
- Active M&A pipeline: Beyond CI Medical, management described its acquisition pipeline as active, supported by an expanded credit facility and disciplined approach to strategic fit and valuation. The company is preparing to pursue larger targets as its platform grows.
Drivers of future performance
Management expects future performance to be driven by continued organic MedTech growth, expanded manufacturing capacity, and disciplined M&A, while monitoring cost trends and execution risks.
- DAS Medical capacity expansion: Investments in DAS Medical are set to deliver new production capacity, supporting further double-digit growth in this segment. Management sees three drivers: ongoing benefits from long-term agreements, full-year contributions from newly launched programs, and rising demand for robotic surgical platforms.
- AJR transition completion: The ongoing transfer of high-labor AJR product lines to the Dominican Republic is expected to yield further margin improvement once completed. Management anticipates these operational moves will help maintain gross margins in the 28%-31% range and deliver additional cost efficiencies in 2027.
- Disciplined acquisitions and platform growth: Management continues to prioritize acquisitions that expand UFP Technologies’ capabilities, especially in plastics and adjacent product lines. The expanded credit facility enables the company to pursue larger targets while maintaining a conservative leverage profile, but integration and execution on new deals remain key risks.
Catalysts in upcoming quarters
Looking ahead, the StockStory team will be monitoring (1) progress on completing the AJR production transfer to the Dominican Republic and its margin impact, (2) the pace and profitability of DAS Medical’s capacity ramp-up and growth in robotic surgical platforms, and (3) execution on larger acquisitions and integration of CI Medical. Continued improvement in operational efficiency and successful scaling of new programs will also be key indicators of future performance.
UFP Technologies currently trades at $327.34, up from $280.32 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Stocks that trumped tariffs
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
